– LAKELAND, FL. Marodyne Medical today announced the formation of a Scientific Advisory Board that will work in tandem with executive leadership to guide the company in its mission to develop safe and effective non-drug treatments for acute injury and chronic metabolic diseases.
Clinton Rubin, Ph.D., Chief Scientific Officer of Marodyne, stated: “It is a wonderful vote of confidence for Marodyne to have been able to recruit such an outstanding panel of scientists and clinicians to our Scientific Advisory Board. We now have a superb resource to help us define our long range scientific plan and research and development targets, as well as to join us in identifying new areas of emphasis for of technologies and intellectual property. The SAB represents an international power-house of scientific expertise in areas ranging from osteoporosis, diabetes, metabolic disorders, obesity, trauma and reconstruction, rehabilitative medicine and stem cell biology. This is a very exciting advance for our young company.”
Lance McNeill, CEO of Marodyne, continued: “The main function of this internationally renowned SAB will be to provide the senior members of Marodyne with insight into the scientific basis of the anabolic nature of the Low Intensity Vibration (LIV) signal. Several members have received funding for their research from the National Institutes of Health, NASA, and the U.S. Army. It is a very exciting time for our company.”
Scientific Advisory Board Members
Scott Boden, M.D.
John B. Buse, M.D., Ph.D.
Victor Frankel, M.D., Ph.D., KNO
Vicente Gilsanz, M.D., Ph.D.
Douglas Kiel, M.D., MPH
Stefan Judex, Ph.D.
Mary B. Leonard, M.D., MSCE
Takashi Matsushita, M.D., PhD
Jeffrey Pessin, Ph.D.
Clifford J. Rosen, M.D.
Janet Rubin, M.D.
